Free Trial
NASDAQ:IXHL

Incannex Healthcare Q4 2025 Earnings Report

Incannex Healthcare logo
$0.59 0.00 (-0.02%)
Closing price 09/26/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+0.86%)
As of 09/26/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incannex Healthcare EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Incannex Healthcare Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Incannex Healthcare Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Incannex Healthcare Earnings Headlines

Incannex Healthcare (IXHL) Projected to Post Earnings on Monday
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.tc pixel
See More Incannex Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email.

About Incannex Healthcare

Incannex Healthcare (NASDAQ:IXHL) Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation. Lead programs target pulmonary hypertension, refractory epilepsy, and chronic cough, with formulations designed for inhalation delivery. In addition, Incannex is advancing studies in post-viral syndromes such as long COVID, exploring the anti-inflammatory and neuroprotective properties of its compounds. Preclinical work and early-phase trials have provided proof-of-concept data supporting further clinical investigation.

Incannex holds an expanding portfolio of patents covering its inhalation devices, formulation technologies and combination drug compositions. The company collaborates with contract research organizations and academic institutions to oversee regulatory filings, toxicology studies and pharmacokinetic assessments. By building a comprehensive intellectual property estate, Incannex aims to position itself for strategic partnerships or licensing agreements upon completion of pivotal trials.

Founded in 2017, Incannex has grown from a research start-up into a development-stage biotech enterprise. Its management team brings experience in drug development, regulatory affairs and commercial strategy, guiding the company through cross-listings on the Australian Securities Exchange and the NASDAQ. With clinical programs underway in Australia and the U.S., Incannex Healthcare is advancing toward proof-of-efficacy studies that could inform its pathway to market for novel cannabinoid-based therapeutics.

View Incannex Healthcare Profile

More Earnings Resources from MarketBeat